Side-by-side · Research reference

AHK-CuvsARA 290

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED14/43 cited

BPhase 2HUMAN-REVIEWED17/59 cited

AHK-Cu

Tripeptide-Copper Complex · Cosmetic

10⁻¹² – 10⁻⁹ MActive range (in vitro)Pyo 2007

Dermal papilla cellsPrimary targetPyo 2007

TopicalRoute

Topical · Scalp / Skin

ARA 290

EPO-Derived Peptide · Innate Repair Receptor Agonist

4 mgDaily doseBrines 2015 Culver 2017

28 daysPhase 2 durationCulver 2017

Non-erythropoieticSafety profileBrines 2015 Liu 2014

SQ · DailyBrines 2015 Culver 2017

01Mechanism of Action

Parameter

AHK-Cu

ARA 290

Primary target

Dermal papilla cells (DPCs) — specialized fibroblasts in hair follicle morphogenesisPyo 2007

Innate repair receptor (EPO receptor / CD131 heterodimer)

Pathway

AHK-Cu → DPC proliferation → VEGF elevation, TGF-β1 suppression → Angiogenesis, follicle elongationPyo 2007

EPO/CD131 → JAK2 activation → PI3K/AKT, MAPK signaling → anti-inflammatory, anti-apoptotic cascades

Downstream effect

Stimulates hair follicle elongation ex vivo, reduces dermal papilla cell apoptosis, elevates Bcl-2/Bax ratio, reduces cleaved caspase-3 and PARPPyo 2007

Tissue protection, nerve fiber regeneration, suppression of inflammatory macrophage activation, altered T-cell differentiation (↑Treg, ↑Th2, ↓Th1)Liu 2014 Culver 2017

Feedback intact?

—

N/A — does not interact with hematopoietic EPO receptorLiu 2014

Origin

Synthetic tripeptide with Cu²⁺ chelation — alanine substitution variant of GHK-Cu

11-amino-acid sequence from EPO helix B, engineered to eliminate hematopoietic activity while retaining tissue-protective properties

Antibody development

—

Not reported in clinical trials

02Dosage Protocols

Parameter

AHK-Cu

ARA 290

Effective concentration (in vitro)

10⁻¹² – 10⁻⁹ MPyo 2007

Stimulated human hair follicle elongation ex vivo and DPC proliferation in vitro.

—

Topical formulation

0.001–0.01% (estimated cosmetic range)

No standardized human protocol published — extrapolated from in vitro data.

—

Frequency

Once or twice daily (topical application)

Once daily

Self-administered subcutaneously.

Route

Topical — scalp or dermal application

SubcutaneousBrines 2015

Evidence basis

Ex vivo hair follicle / in vitro DPC studiesPyo 2007

Phase 2 RCTsCulver 2017 Brines 2015

64-subject sarcoidosis trial, type 2 diabetes trial.

Duration

Not established — cosmetic protocols typically 8–12 weeks

28 days (Phase 2)Culver 2017

Corneal nerve improvements observed by day 28.

Standard dose (Phase 2)

—

4 mg / dayBrines 2015 Culver 2017

Sarcoidosis SFN and diabetic neuropathy trials.

Timing

—

Any time of day

No circadian dependence reported.

03Metabolic / Fat Loss Evidence

Parameter

AHK-Cu

ARA 290

Primary effect

—

Improved metabolic control (HbA1c, fasting glucose)Brines 2015

Secondary to neuropathy treatment; direct lipolytic effects not established.

HbA1c

—

Significant reduction vs placebo

Observed in type 2 diabetes + neuropathy trial.

Fasting glucose

—

Improved in ARA 290 group

Body composition

—

Not directly quantified

Fat loss not a primary endpoint; metabolic improvements may reflect insulin sensitivity.

04Side Effects & Safety

Parameter

AHK-Cu

ARA 290

Local irritation

Mild erythema, pruritus at application site (copper peptide class effect)

—

Copper sensitivity

Rare hypersensitivity reaction in copper-sensitive individuals

—

Systemic absorption

Minimal via topical route — systemic copper toxicity unlikely at cosmetic doses

—

Data limitations

No published human safety trials — cosmetic use presumed safe per class precedent (GHK-Cu)

—

Injection site reaction

—

Mild, transient

Hematopoiesis

—

None — non-erythropoietic

Distinguishes ARA 290 from native EPO.

Cardiovascular

—

No thrombotic events or hypertension reported

Immunogenicity

—

No antibody formation reported

Tolerability

—

Well-tolerated in Phase 2 trialsCulver 2017 Brines 2015

Absolute Contraindications

AHK-Cu

·Known copper allergy or Wilson's disease

ARA 290

·Hypersensitivity to ARA 290

Relative Contraindications

AHK-Cu

·Broken or inflamed skin (increased absorption risk)
·Concurrent use of other copper-containing formulations

ARA 290

·Active malignancy (theoretical EPO-axis concern; not observed in trials)

05Administration Protocol

Parameter

AHK-Cu

ARA 290

1. Topical application

Apply to clean, dry scalp or target dermal area. Typical cosmetic formulations: 0.001–0.01% AHK-Cu in serum or cream base.

Reconstitute lyophilised powder per manufacturer instructions. Use sterile technique.

2. Frequency

Once or twice daily. Evening application preferred for overnight contact time.

Subcutaneous — abdomen, thigh, or upper arm. Rotate sites to avoid lipohypertrophy.

3. Scalp preparation

For hair growth: apply directly to scalp, massage gently. No need to rinse. Allow absorption for minimum 2–4 hours.

Once daily, any time of day. Self-administered in Phase 2 trials.Brines 2015

4. Storage

Room temperature, protected from light. Copper complexes may degrade in UV exposure.

4 mg daily for 28 days (Phase 2 protocol). Duration for chronic use not established.Culver 2017

5. Duration

Minimum 8–12 weeks to assess efficacy in hair growth applications, per typical cosmetic peptide protocols.

Lyophilised: store at controlled room temperature. Reconstituted: refrigerate, use within specified timeframe.

06Stack Synergy

AHK-Cu

+ GHK-Cu

Moderate

View GHK-Cu →

Both tripeptide-copper complexes share overlapping angiogenic and wound-healing mechanisms (VEGF elevation, TGF-β modulation, fibroblast proliferation). AHK-Cu's alanine substitution may offer distinct receptor affinity or pharmacokinetics. Co-formulation could provide complementary dermal signaling, though no direct synergy studies exist. Often used interchangeably or in alternating protocols.

AHK-Cu: 0.001–0.01% topical · AM
GHK-Cu: 0.001–0.01% topical · PM
Frequency: Daily alternation or combined formulation
Primary benefit: Comprehensive dermal regeneration, angiogenesis, hair follicle support

ARA 290

+ BPC-157

Moderate

View BPC-157 →

ARA 290 targets the innate repair receptor (EPO/CD131) for nerve regeneration and anti-inflammatory signaling, while BPC-157 promotes angiogenesis and tissue repair through distinct mechanisms (likely involving VEGF, growth hormone receptor pathways). Combined, they may address both neuroinflammation and structural tissue repair in neuropathy or injury models. No direct clinical data; mechanistic overlap in tissue protection.

ARA 290: 4 mg SQ · daily
BPC-157: 250–500 mcg SQ · daily
Frequency: Once daily, same or separate injections
Primary benefit: Nerve regeneration, pain reduction, tissue healing